|
|
Research progress of end-stage renal disease complicated with renal cell carcinoma |
LIU Wei1 YU Chunzhao2 YANG Jian1 JIANG Rongjiang1 |
1.Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Jiangsu Province, Nanjing 210011, China;
2.Department of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Jiangsu Province, Nanjing 210011, China |
|
|
Abstract The increase of the morbidity and mortality of end-stage renal disease is the focus of chronic disease prevention and treatment in China. Renal cell carcinoma associated with end-stage renal disease is the leading cause of death in patients with end-stage renal disease. The pathological types of end-stage renal disease associated renal cell carcinoma include conventional renal cell carcinoma histological subtypes and unique histological subtypes, such as acquired cystic kidney disease associated renal cell carcinoma and clear cell papillary renal cell carcinoma, which are difficult to diagnose and treat. This article reviews the etiology, incidence, pathogenesis, pathological classification, and prognosis of end-stage renal disease associated renal cell carcinoma, which is helpful to improve the understanding of end-stage renal disease associated renal cell carcinoma in urinary diseases.
|
|
|
|
|
[1] 何冰,李玉军,张伟,等.终末期肾病合并肾细胞癌的临床病理学特征[J].中华病理学杂志,2019,48(11):846-850.
[2] Dunnill MS,Millard PR,Oliver D. Acquired cystic disease of the kidneys:a hazard of long-term intermittent maintenance haemodialysis [J]. J Clin Pathol,1977,30(9):868-877.
[3] Konishi F,Mukawa A,Kitada H. Acquired cystic disease of the kidney and renal cell carcinoma on long term hemodialysis four surgical cases of young adults in Japan [J]. Acta Pathol Jpn,1980,30(5):847-858.
[4] Lin J,Kamamia C,Shriver CD,et al. Race and renal cell carcinoma stage at diagnosis:an analysis of the Surveillance,Epidemiology,and End Results data [J]. Eur J Cancer Prev,2019,28(4):350-354.
[5] Sarasin FP,Wong JB,Levey AS,et al. Screening for acquired cystic kidney disease:a decision analytic perspective [J]. Kidney Int,1995,48(1):207-219.
[6] Giovanni,Lughezzani,Marco,et al. Gender-specific risk factors for renal cell carcinoma:a systematic review [J]. Curr Opin Urol,2019,29(3):272-278.
[7] Eggers H,Güler F,Ehlers U,et al. Renal cell carcinoma in kidney transplant recipients:descriptive analysis and overview of a major German transplant center [J]. Future Oncol,2019,15(32):3739-3750.
[8] 施珍,金领微,高依依,等.血液透析患者获得性肾囊肿的临床回顾分析[J].中国中西医结合肾病杂志,2014,15(1):46-47.
[9] Kondo T,Sassa N,Yamada H,et al. Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease:a multi-institutional central pathology study [J]. Pathology,2021,53(6):720-727.
[10] Toyokuni S. The origin and future of oxidative stress pathology:From the recognition of carcinogenesis as an iron addiction with ferroptosis-resistance to non-thermal plasma therapy [J]. Pathol Int,2016,66(5):245-259.
[11] Tsuzuki T,Iwata H,Murase Y,et al. Renal tumors in end-stage renal disease:A comprehensive review [J]. Int J Urol,2018,25(9):780-786.
[12] Fleming S. Renal cell carcinoma in acquired cystic kidney disease [J]. Histopathology,2010,56(3):395-400.
[13] Liu C,Gong X,Zhang S,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma with caval tumour thrombus [J]. Eur Urol Suppl,2019,18(1):e2100.
[14] Linehan WM,Spellman PT,Ricketts CJ,et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma [J]. N Engl J Med,2016,374(2):135-145.
[15] Moch H,Ohashi R. Chromophobe renal cell carcinoma:current and controversial issues [J]. Pathology,2020,53(1):101-108.
[16] Ishihara H,Yamashita S,Liu Y,et al. Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease [J]. Cancer Sci,2020,111(11):4276-4287.
[17] Nouh MA,Kuroda N,Yamashita M,et al. Renal cell carcinoma in patients with end-stage renal disease:relationship between histological type and duration of dialysis [J]. BJU Int,2010,105(5):620-627.
[18] Sassa N,Hattori R,Tsuzuki T,et al. Renal cell carcinomas in haemodialysis patients:does haemodialysis duration influence pathological cell types and prognosis? [J]. Nephrol Dial Transplant,2011,26(5):1677-1682.
[19] Moch H,Cubilla AL,Humphrey PA,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs——Part A:Renal,Penile,and Testicular Tumours [J]. Eur Urol,2016,70(1):93-105.
[20] 杨建勋,付启忠,董圣芳,等.获得性肾囊性疾病合并肾癌11例临床分析[J].中华泌尿外科杂志,2011,32(2):805-807.
[21] Cossu-rocca P,Eble JN,Zhang S,et al. Acquired cystic disease-associated renal tumors:an immunohistochemical and fluorescence in situ hybridization study [J]. Mod Pathol,2006,19(6):780-787.
[22] Chrabańska M,Jakub R,Bogna D. Bilateral and Multifocal Acquired Cystic Disease-Associated Renal Cell Carcinomas in Patient With End-Stage Renal Disease Caused by Systemic Lupus Erythematosus [J]. Int J Surg Pathol,2021,29(2):198-204.
[23] Zhao J,Eyzaguirre E. Clear Cell Papillary Renal Cell Carcinoma [J]. Arch Pathol Lab Med,2019,143(9):1154-1158.
[24] Griffin BB,Lin X. Cytomorphologic analysis of clear cell papillary renal cell carcinoma:Distinguishing diagnostic features [J]. Cancer Cytopathol,2021,129(3):192-203.
[25] Williamson SR. Clear cell papillary renal cell carcinoma:an update after 15 years [J]. Pathology,2021,53(1):109-119.
[26] Brown JG,Folpe AL,Rao P,et al. Primary Vascular Tumors and Tumor-like Lesions of the Kidney:A Clinicopathologic Analysis of 25 Cases [J]. Am J Surg Pathol,2010,34(7):942-949.
[27] Zhou J,Yang X,Zhou L,et al. Anastomosing Hemangioma Incidentally Found in Kidney or Adrenal Gland:Study of 10 Cases and Review of Literature [J]. Urol J,2020,17(6):650-656.
[28] Kuroda N,Ohe C,Deepika S,et al. Review of renal anastomosing hemangioma with focus on clinical and pathological aspects [J]. Pol J Pathol,2016,67(2):97-101.
[29] Steward JE,Kern SQ,Liang C,et al. Clear cell papillary renal cell carcinoma:Characteristics and survival outcomes from a large single institutional series [J]. Urol Oncol,2021,39(6):370.e21-370.e25. |
|
|
|